SCHEMBL10219571

SCHEMBL10219571

Cc1nc2cc(-c3nc4ccccc4o3)ccc2n1C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CCR5 P51681 5/20 0.46
▸ CETP P11597 1/20 0.46
▸ OPRM1 P35372 1/20 0.45
▸ OPRD1 P41143 1/20 0.45
▸ OGFRL1 Q5TC84 1/20 0.45
▸ PKM P14618 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ GPR119 Q8TDV5 6/20 0.44
▸ LMNA P02545 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ MAPK1 P28482 2/20 0.42
▸ MET P08581 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2687827 0.90 LMNA (0.46) PKMUSP2LMNASMN1; SMN2KDM4E
SCHEMBL2688265 0.83 ALDH1A1 (0.47) PKMUSP2LMNASMN1; SMN2KDM4E
SCHEMBL947135 0.82 LMNA (0.62) CCR5OPRM1OPRD1OGFRL1GPR119
SCHEMBL2687957 0.80 EP300 (0.48) PKMUSP2LMNASMN1; SMN2KDM4E
SCHEMBL2686300 0.80 ALDH1A1 (0.46) PKMUSP2LMNASMN1; SMN2KDM4E
SCHEMBL2687060 0.80 KDM4E (0.54) CCR5OPRM1PKMUSP2LMNA
SCHEMBL2686439 0.80 SMN1; SMN2 (0.46) PKMUSP2SMN1; SMN2KDM4EALDH1A1
SCHEMBL16015419 0.79 ALDH1A1 (0.44) PKMUSP2LMNASMN1; SMN2KDM4E
SCHEMBL2688684 0.79 MET (0.44) PKMUSP2SMN1; SMN2KDM4EALDH1A1
SCHEMBL2688665 0.78 USP2 (0.42) PKMUSP2LMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 CCR5 420/4885CETP 777/4885OPRM1 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback